Skip to Main Content

Novo Nordisk, the maker of the wildly popular obesity drug Wegovy, said Thursday it would temporarily limit some “starter” doses for new patients in the United States to ensure a steady supply for people already on the medication. 

The company will cut the supply of lower-strength doses available that new patients start with, it said. 


The announcement from Novo is the latest demonstration of the surging interest for the weight-loss medication and the company’s struggles to meet that demand. Some patients have resorted to trying to find the active ingredients themselves. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!